A hydroperoxy reductase probably reduces 7,17-dihydroperoxy-docosapentaenoic acid (7,17-diHp-DPAn-3) to the resolvin 7,17-dihydroxy-docosapentaenoic acid (RvD5n-3DPA) (Dalli et al. 2013). Treatment with RvD5n-3DPA reduced colitis and intestinal ischemia/reperfusion-induced inflammation in mice and reduced human neutrophil-endothelial cell interactions with TNF-α-activated human endothelial monolayers (Gobbetti et al. 2017). Although this is a proposed biosynthetic route for the formation of DPA-n-3 resolvins, it is assumed DPAn-3-derived SPMs follow a similar synthesis route to DHA- and EPA-derived SPMs.